Nature communications · 2025
A clonally expanded nodal T-cell population diagnosed as T-cell lymphoma after CAR-T therapy.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maurer Katie, Weir Jackson A, Nagler Adi, Haradhvala Nicholas J, Bharadwaj Hariharan, Shapiro Jacob, Alakwe Somkene, Kumar Vipin, Waller Brianna, McDonough Mikaela, Dela Cruz Jamie, Luna Loida, Lin Emma, Gong Linsey, Gong Qiyu, Borji Mehdi, Michaels Phillip D, Laubach Jacob P, Pinkus Geraldine, Getz Gad, Wu Catherine J, Chen Fei, Jacobson Caron
Аннотация
Reports of secondary malignancies after chimeric antigen receptor (CAR)-T and possible CAR-T derived malignant transformation necessitate caution. Here we describe a patient with diffuse large B-cell lymphoma who developed new lymphadenopathy 2.5 years after CAR-T in the context of COVID-19 infection with histopathologic features consistent with T-cell lymphoma (TCL). Deep molecular interrogation with genomic sequencing and single-cell spatial transcriptomics reveals a highly proliferative clonal T-cell population co-expressing CD4 and CD8 with biallelic TCR rearrangement and no evidence of the CAR construct. The expanded clonotype displayed T follicular helper (TFH) cell transcriptomic programs and occupies immune-excluded spatial niches within the lymph node, supportive of TFH-like neoplastic T cell behavior. Remarkably, the lymphadenopathy spontaneously resolved on interval imaging. Our data underscore the need for better understanding of post-CAR-T clonal T-cell lymphoproliferative disorders to avoid unnecessary treatment and higher specificity in diagnostic methods for TCL.